Improved demand and high EBITA margin Third quarter 2025Order intake increased by 3% and amounted to SEK 7,735 million (7,537). For comparable units, the increase was 3%.Net sales decreased by 2% to S ...
NIBD/EBITDA before special items was 2.5x at the end of Q3 2025. The leverage ratio is within the target range of 2.0-3.0x and the share buyback program is ongoing. Embla Medical bought back 525,733 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback